Cargando…
Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
Background and Objective: Inhibition of thrombosis and platelet aggregation through a thromboxane synthetase inhibitor proved to be an effective and promising treatment for cardiovascular and/or cerebrovascular disease (CCVD) patients. This phase I study evaluated the safety, tolerability, and pharm...
Autores principales: | Zou, Chan, Zuo, Xiaocong, Huang, Jie, Hua, Ye, Yang, Shuang, Yang, Xiaoyan, Guo, Can, Tan, Hongyi, Chen, Jun, Chu, Zhaoxing, Pei, Qi, Yang, Guoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821791/ https://www.ncbi.nlm.nih.gov/pubmed/31708774 http://dx.doi.org/10.3389/fphar.2019.01231 |
Ejemplares similares
-
Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase
por: Li, Ping, et al.
Publicado: (2020) -
Profiling and Preparation of Metabolites from Pyragrel in Human Urine by Online Solid-Phase Extraction Coupled with High Performance Liquid Chromatography Tandem Mass Spectrometry Followed by a Macroporous Resin-Based Purification Approach
por: Zhao, Xin, et al.
Publicado: (2017) -
Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
por: Nie, Shanshan, et al.
Publicado: (2022) -
Single- and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers
por: Chen, Lulu, et al.
Publicado: (2018) -
Measurement of Thromboxane Biosynthesis in Health and Disease
por: Patrono, Carlo, et al.
Publicado: (2019)